Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (386)	2/7/1999 9:42:00 PM
From: Arthur Radley	Respond to of 613

ivanhoe.com Concerning ATRX, I said earlier I wasn't going to beat the drum tooo loud on this one. However, I'm getting out a extra large set of drum sticks to start a drum roll. For those interested, take a look at the VectorVest report and look at the last two days trading pattern in this stock.

To: Mike McFarland who wrote (386)	2/10/1999 7:47:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 613

We might see a little action in GLGC today. A very positive article in today's WSJ about insider buying in various biotechs. GLGC is mentioned in detail because insiders have bought 160,000 shares in late 1998. As for Entremed, stand clear as Bristol Meyer has pulled the plug on developing their drug. If only I had listened about 2 months ago when it was reported that they couldn't duplicate the results in their labs for endostatin(sp).